Locate your nearest distributor

Location:
Type:
Text search:
Username:
Password:
Forgot password?

News Archive

Biohit Oyj B-shares Subscribed with Stock Options I 2013

06.11.2017 09:30

Biohit Oyj Total number of voting rights and capital November 6, 2017 at 09:30 a.m. (EEST) Read more

An important patent granted to Biohit Acetium® Capsule in Japan

11.09.2017 10:30

Biohit Oyj press release 11 September 2017 at 10:30 am. Local time (EEST) Biohit Acetium® Capsule was granted in July 21, 2017 an important patent in Japan, valid until May 22, 2027 (Patent No: 6178657). The Patent is entitled: “Composition and method for binding acetaldehyde in stomach.” and it covers comprehensively all the fields of application of the Biohit Acetium® Capsule, as well as its eventual future modifications in composition, dosage and indications for use. Read more...

A new meta-analysis from independent scientists in Italy confirms the accuracy of Biohit GastroPanel® in diagnosis of atrophic gastritis

04.09.2017 09:30

Biohit Oyj press release 4 September 2017 at 9:30 am. local time (EEST) A group of prominent gastroenterologists in Bologna, Italy, collaborating with a biostatistician from Leeds University, UK, published an important meta-analysis in an esteemed gastroenterology journal (Alimentary Pharmacology & Therapeutics)(1). Read more

BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2017

17.08.2017 09:30

Biohit Oyj Half Year Financial Report 17 August 2017 at 9:30 am local time (EEST) SUMMARY January-June 2017 Net sales grew by 6.7 % compared to H1/2016 Net sales EUR 4.1 million (EUR 3.8 million) Operating profit EUR 7.4 million including the profit of EUR 8.4 million booked from the joint venture exit (EUR -2.1 million) The profit for the reporting period was EUR 7.2 million (EUR -2.1 million) Net sales from international operations 95.0 % (90.5 %) of total net sales Equity ratio 89.6 % (85.4 %) PRESIDENT AND CEO SEMI KORPELA: ”During th...

Biohit GastroPanel® was shown to be an accurate predictor of gastric cancer risk during a 12-year follow-up of 12.000 people in China

16.08.2017 14:45

Biohit Oyj press release 16 August 2017 at 2:45 pm. local time (EEST) A Chinese research group headed by Prof. Yuan Yuan (Shenyang City, Liaoning, China), collaborating with scientists from MD Anderson Cancer Center (Houston, Texas, USA), published an important study in a leading gastroenterology journal (American Journal of Gastroenterology 2017;112:704–715)(1). Read more

The results of Biohit’s second smoking intervention trial have been published

02.08.2017 09:30

Biohit Oyj press release 02 August 2017 at 9:30 am. local time (EEST) The results of the Biohit’s second large-scale smoking intervention trial have been published in the international cancer journal: Anticancer Research. This randomized placebo-controlled trial (RCT) comprising almost 2000 smokers was completed in May 2017. Read more...

Chinmax Medical Systems Inc. to distribute Acetium® Lozenge in China

05.06.2017 09:30

Biohit Oyj press release 5 June 2017 at 9:30 am. local time (EEST) Biohit Oyj and Chinmax Medical Systems Inc. have signed an agreement for the distribution of the Acetium lozenge in China. The agreement has been signed for a preliminary period of seven years and includes an option and a letter of intent for a joint venture arrangement and local production if the sales targets set out in the agreement are met. Read more...

Ownership arrangement in Biohit Oyj’s Chinese Joint Venture completed

31.05.2017 14:00

Biohit Oyj Inside information, 31st May, 2017 at 2 pm local time (EEST) On the 2nd of January 2017 Biohit Oyj made an announcement regarding the share capital reduction of its joint venture Biohit HealthCare (Hefei) Co. Ltd thereby assigning ownership in the company. read more

Biohit Oyj B-shares subscribed with Stock Options I 2013 B

29.05.2017 09:45

Biohit Oyj Total number of voting rights and capital May 29, 2017 at 9:45 am (EEST) A total number of 56 452 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 B between 10 March 2017 and 4 May 2017. These shares have been entered into the trade register on May 29, 2017, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading is expected to begin on NASDAQ Helsinki as of May 30, 2017 together with the existing B-shares. read more...

Biohit Acetium® lozenge is a highly effective means to stop smoking

22.05.2017 09:30

Biohit Acetium® lozenge is a highly effective means to stop smoking – results confirmed in a new large-scale trial. Read more ...

Lea Paloheimo appointed Biohit Oyj’s R&D and production director

04.05.2017 10:00

Lea Paloheimo, PhD (clinical biochemistry), has been appointed Biohit Oyj’s R&D and production director. Lea Paloheimo has been a member of the Biohit Oyj’s management team since 2006. Read more

Constitutive meeting of Biohit Oyj’s Board of Directors

27.04.2017 09:30

Biohit Oyj Other information disclosed according to the rules of the Exchange April 27, 2017 at 9:30 am local time (EEST) Biohit Oyj’s Board of Directors has in its meeting yesterday elected Mr Osmo Suovaniemi as the Chairman of the Board of Directors. Read more

Decisions of the Annual General Meeting of Biohit Oyj

26.04.2017 19:30

Biohit Oyj Decisions of general meeting April 26, 2017 at 7:30 pm local time (EEST) The Annual General Meeting (AGM) of Biohit Oyj held on Wednesday April 26, 2017 approved the financial statements of the parent company and the consolidated financial statements, and discharged the members of the Board of Directors and the President and CEO from liability for the financial year 2016. Read more...

Biohit Oyj B-shares subscribed with Stock Options I 2013 B

20.04.2017 09:30

Biohit Oyj Total number of voting rights and capital April 20, 2017 at 9:30 am (EEST) A total number of 21 858 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 B between 2 December 2016 and 9 March 2017. These shares have been entered into the trade register on April 20, 2017, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading is expected to begin on NASDAQ Helsinki as of April 21, 2017 together with the existing B-shares. Read more...

NOTICE OF BIOHIT OYJ’S ANNUAL GENERAL MEETING

03.04.2017 09:30

Biohit Oyj Notice to general meeting April 3, 2017 at 9:30 am local time (EEST) Biohit Oyj shareholders are invited to attend the company’s Annual General Meeting to be held on Wednesday, April 26, 2017 starting at 5:00 pm at Pörssitalo. The address is Fabianinkatu 14, 00100 Helsinki. The reception of shareholders registered for the meeting and the distribution of voting slips will commence at 4:00 pm. Read more...

Publication of Biohit Oyj Annual Report 2016

23.03.2017 09:30

Biohit Oyj Annual Financial Report March 23, 2017 at 9:30 am local time (EET) Biohit Oyj’s Annual Report 2016 is published today in PDF format. Read more

BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2016

20.02.2017 09:30

Biohit Oyj Financial Statement Release, 20 February 2017 at 9:30 am local time (EET). Read more

Biohit Oyj’s CEO Semi Korpela will return to work on 20.2.2017

20.02.2017 09:29

Biohit Oyj Stock Exchange Release February 20, 2017 9:29 am local time (EEST) Biohit Oyj announced on January 5, 2017 that CEO Semi Korpela would take a sick leave of approximately one month, related to pneumonia and recovery from it. Korpela has recovered from his illness and will return to work on 20.2.2017. Read more

Biohit Oyj CEO Semi Korpela takes sick leave

05.01.2017 13:00

Biohit Oyj Stock Exchange Release January 5, 2017 at 1:00 pm local time (EEST) Starting from January 5, 2017 Biohit Oyj´s CEO Semi Korpela will take a sick leave of approximately one month related to pneumonia. During Semi Korpela´s sick leave, his deputy will be Biohit Oyj`s CFO Niklas Nordström. Read more

Ownership arrangement in Biohit Oyj’s Chinese Joint Venture – 2017 operating result expected to be positive

02.01.2017 09:30

Biohit Oyj Stock Exchange Release January 2, 2017 at 09:30 am local time (EEST) Biohit Oyj and Anhui Wisdom-Win Investment Co. Ltd have signed a resolution authorised by shareholders of Biohit HealthCare (Hefei) Co. Ltd, a joint venture operating in Hefei, China, concerning reduction of the joint venture share capital for an amount equal to Biohit Oyj’s shareholding. Biohit Oyj owns 40% of the company, and the agreement is for reduction of the entire share capital. As a result of the transaction Biohit Oyj estimates its operating result to turn clearly positive for 2017. Re...